tiprankstipranks
Trending News
More News >
Connect Biopharma Holdings (CNTB)
NASDAQ:CNTB
US Market

Connect Biopharma Holdings (CNTB) AI Stock Analysis

Compare
85 Followers

Top Page

CN

Connect Biopharma Holdings

(NASDAQ:CNTB)

Rating:49Neutral
Price Target:
Connect Biopharma Holdings' overall score reflects the challenges of unprofitability and negative cash flow despite recent revenue growth and a strong balance sheet. Technical indicators suggest a bearish trend, while the valuation highlights the risks typical of early-stage biotech firms. However, the positive corporate event regarding FDA support for Phase 2 trials offers a promising growth opportunity in the pipeline, improving the outlook.
Positive Factors
Market Opportunity
CNTB's recent shift in strategy towards targeting asthma and COPD patients within the emergency department/hospital settings represents an attractive opportunity.
Regulatory Progress
CNTB announced positive feedback from its Type C meeting with the FDA and is on track to initiate parallel Phase 2 proof-of-concept trials for lead asset rademikibart.
Negative Factors
Clinical Risks
Risks include safety signals emerge with any of the company’s clinical or preclinical programs, efficacy from clinical programs is lower than expected, or the company’s studies do not achieve statistical significance.
Financial Needs
Financing requirements for the business assume cash runway into 2027 and approximately $150M additional financing needed through 2038.

Connect Biopharma Holdings (CNTB) vs. SPDR S&P 500 ETF (SPY)

Connect Biopharma Holdings Business Overview & Revenue Model

Company DescriptionConnect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.
How the Company Makes MoneyConnect Biopharma Holdings makes money through the development and commercialization of its proprietary drugs targeted at T cell-driven inflammatory diseases. The company's revenue model primarily involves out-licensing its drug candidates to larger pharmaceutical companies, which may provide upfront payments, milestone payments, and royalties on future sales. Additionally, Connect Biopharma may engage in strategic collaborations with other biopharmaceutical companies to co-develop and co-market its products, thereby sharing the risks and rewards of drug development. However, as a clinical-stage company, significant revenue generation depends on successfully navigating the regulatory approval process and bringing its therapies to market.

Connect Biopharma Holdings Financial Statement Overview

Summary
Connect Biopharma Holdings shows early signs of growth with its first revenue generation, but it remains in a challenging financial position with persistent losses and negative cash flows. The balance sheet shows some strength with low leverage, but historical financial instability poses a risk.
Income Statement
45
Neutral
Connect Biopharma Holdings' income statement shows a significant improvement in revenue from $0 to $26.03 million in the most recent year, marking the first occurrence of revenue generation. However, the company remains unprofitable with a negative net income and EBIT margin. The net profit margin is negative due to persistent losses, but the revenue growth is a positive sign of potential progress.
Balance Sheet
55
Neutral
The balance sheet reflects a relatively healthy equity position with stockholders' equity at $92 million, indicating potential for stability. The debt-to-equity ratio is low, reflecting low leverage, which is a positive aspect. However, historical negative equity and high liabilities in previous years suggest potential financial risk.
Cash Flow
40
Negative
The cash flow statement indicates ongoing cash outflows with negative operating and free cash flows, although there is a slight improvement compared to prior years. The free cash flow to net income ratio is negative, indicating cash flow struggles, but reduced negative cash flow signals potential for future improvement.
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
26.03M0.000.000.000.00
Gross Profit
25.37M-988.00K-1.03M0.000.00
EBIT
-22.45M-62.07M-117.66M-99.15M-30.30M
EBITDA
-22.45M-58.37M-111.31M-204.93M-118.21M
Net Income Common Stockholders
-15.63M-59.50M-116.42M-205.21M-120.30M
Balance SheetCash, Cash Equivalents and Short-Term Investments
93.71M118.65M164.65M268.02M156.74M
Total Assets
101.28M125.89M177.01M291.39M166.19M
Total Debt
178.00K465.00K437.88K124.52K139.86K
Net Debt
-78.05M-105.54M-79.93M-267.90M-154.59M
Total Liabilities
9.12M24.85M16.81M18.82M323.20M
Stockholders Equity
92.17M101.04M-463.76M272.57M-157.01M
Cash FlowFree Cash Flow
-24.36M-48.22M-103.55M-93.03M-27.95M
Operating Cash Flow
-23.61M-47.93M-99.27M-85.57M-25.61M
Investing Cash Flow
-3.45M75.16M-83.44M449.15K
Financing Cash Flow
227.00K-246.00K206.66M140.74M

Connect Biopharma Holdings Technical Analysis

Technical Analysis Sentiment
Positive
Last Price1.08
Price Trends
50DMA
0.78
Positive
100DMA
0.82
Positive
200DMA
0.99
Positive
Market Momentum
MACD
0.05
Negative
RSI
77.37
Negative
STOCH
96.77
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CNTB, the sentiment is Positive. The current price of 1.08 is above the 20-day moving average (MA) of 0.83, above the 50-day MA of 0.78, and above the 200-day MA of 0.99, indicating a bullish trend. The MACD of 0.05 indicates Negative momentum. The RSI at 77.37 is Negative, neither overbought nor oversold. The STOCH value of 96.77 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CNTB.

Connect Biopharma Holdings Risk Analysis

Connect Biopharma Holdings disclosed 121 risk factors in its most recent earnings report. Connect Biopharma Holdings reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Connect Biopharma Holdings Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
54
Neutral
$5.34B3.36-45.10%3.39%16.81%-0.03%
49
Neutral
$54.24M-58.89%
46
Neutral
$27.98M-214.26%20.58%15.90%
44
Neutral
$15.80M1.22121.75%
40
Underperform
$48.75M-75.45%14.06%
28
Underperform
$35.66M-916.17%45.15%
$29.23M
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CNTB
Connect Biopharma Holdings
1.08
-0.37
-25.52%
DYAI
Dyadic International
0.92
-0.88
-48.89%
XFOR
X4 Pharmaceuticals
2.74
-26.06
-90.49%
RVPH
Reviva Pharmaceuticals Holdings
0.72
-0.63
-46.67%
PEPG
PepGen Inc.
1.41
-15.39
-91.61%
CAMP
CAMP4 Therapeutics Corporation
1.39
-8.36
-85.74%

Connect Biopharma Holdings Corporate Events

Product-Related AnnouncementsBusiness Operations and Strategy
Connect Biopharma Gains FDA Support for Phase 2 Trials
Positive
Apr 1, 2025

On April 1, 2025, Connect Biopharma announced positive feedback from its Type C meeting with the FDA, which has aligned on the company’s plan to initiate parallel Phase 2 trials of rademikibart for patients with moderate-to-severe asthma or COPD experiencing acute exacerbations. These trials, set to begin in the second quarter of 2025, aim to enroll approximately 160 patients each and will evaluate the efficacy of a single 600 mg subcutaneous dose of rademikibart over 28 days. The company expects to report data from these trials in the first half of 2026, potentially impacting the treatment landscape for asthma and COPD by addressing a significant unmet need.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.